SignalFDA/Bio

GSK EXPANDS MYELOMA PIPELINE IN DEAL WORTH UP TO $750M - SEEKINGALPHA

GSK expands myeloma pipeline via deal worth up to $750M.

What changed

GSK expands myeloma pipeline via deal worth up to $750M.

Why it matters

GSK expands myeloma pipeline via deal worth up to $750M. — impact context not separately stored; see What changed.

Sources